Stock KOD KODIAK SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
3.77 USD +1.89% Intraday chart for Kodiak Sciences Inc. +14.94% +24.01%
02/05 Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate Platform CI
04/04 UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
PR
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
PR
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
PR
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
PR
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
PR
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
PR
Diabetic Retinopathy Pipeline, Clinical Trials, and Key Companies - Ocular Therapeutics , Novartis, Bayer
AQ
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
PR
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
AQ
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PR
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
AQ
Kodiak Sciences : Results of Operations and Financial Condition - Form 8-K
PU
Kodiak Sciences : Clinical Trials at the Summit Annual Meeting
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KOD Stock
  4. News Kodiak Sciences Inc.
  5. Press Releases